All In Biotech

Drug Trial Radar · NCT01532648

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX® 9 mg Extended-release Tablets as Add-on Therapy in Patients With Active, Mild or Moderate Ulcerative Colitis Not Adequately Controlled on a Background Oral 5-ASA Regimen

Last checked: Nov 20, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 510 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

510

Actual

Start

Jan 27, 2012

Primary completion

Oct 2, 2013

Study completion Oct 2, 2013

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Feb 14, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to compare the efficacy and safety of budesonide MMX 9 mg versus placebo as add-on therapy to an existing oral 5-ASA regimen for the induction of remission in participants with active mild or moderate ulcerative colitis (UC).

Conditions

  • Ulcerative Colitis

Interventions

  • Budesonide MMX®Drug

    Oral tablet taken daily in the morning after breakfast.

  • PlaceboDrug

    Matching budesonide MMX placebo oral tablet taken daily in the morning after breakfast.

  • 5-ASADrug

    Acceptable oral 5-ASA medications to be received during the study include: * Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g) * Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g * Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g * Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Achieved Clinical Remission at Day 56Time frame: Baseline up to Day 56

Locations

114 sites in 11 countries. Site status is shown where the registry gives one.

  • Santarus Clinical Investigational Site 1043

    Anaheim, California

  • Santarus Clinical Investigational Site 1071

    Lakewood, California

  • Santarus Clinical Investigational Site 1003

    San Diego, California

  • Santarus Clinical Investigational Site 1063

    Littleton, Colorado

  • Santarus Clinical Investigational Site 1028

    Bristol, Connecticut

  • Santarus Clinical Investigational Site 1035

    Boynton Beach, Florida

  • Santarus Clinical Investigational Site 1045

    Jacksonville, Florida

  • Santarus Clinical Investigational Site 1001

    Largo, Florida

  • Santarus Clinical Investigational Site 1024

    Maitland, Florida

  • Santarus Clinical Investigational Site 1029

    Port Orange, Florida

  • Santarus Clinical Investigational Site 1010

    Winter Park, Florida

  • Santarus Clinical Investigational Site 1002

    Zephyrhills, Florida

  • Santarus Clinical Investigational Site 1050

    Decatur, Georgia

  • Santarus Clinical Investigational Site 1075

    Chicago, Illinois

  • Santarus Clinical Investigational Site 1065

    Oak Lawn, Illinois

  • Santarus Clinical Investigational Site 1058

    Indianapolis, Indiana

  • Santarus Clinical Investigational Site 1032

    Shreveport, Louisiana

  • Santarus Clinical Investigational Site 1044

    Annapolis, Maryland

  • Santarus Clinical Investigational Site 1016

    Chesterfield, Michigan

  • Santarus Clinical Investigational Site 1081

    Novi, Michigan

  • Santarus Clinical Investigational Site 1015

    Wyoming, Michigan

  • Santarus Clinical Investigational Site 1068

    Ypsilanti, Michigan

  • Santarus Clinical Investigational Site 1074

    Rochester, Minnesota

  • Santarus Clinical Investigational Site 1061

    Lebanon, New Hampshire

  • Santarus Clinical Investigational Site 1021

    Cheektowaga, New York

  • Santarus Clinical Investigational Site 1072

    Great Neck, New York

  • Santarus Clinical Investigational Site 1031

    New York, New York

  • Santarus Clinical Investigational Site 1073

    Wilmington, North Carolina

  • Santarus Clinical Investigational Site 1080

    Cincinnati, Ohio

  • Santarus Clinical Investigational Site 1078

    Cleveland, Ohio

  • Santarus Clinical Investigational Site 1082

    Dayton, Ohio

  • Santarus Clinical Investigational Site 1064

    Lancaster, Pennsylvania

  • Santarus Clinical Investigational Site 1006

    Sayre, Pennsylvania

  • Santarus Clinical Investigational Site 1059

    Austin, Texas

  • Santarus Clinical Investigational Site 1039

    Houston, Texas

  • Santarus Clinical Investigational Site 1005

    Pasadena, Texas

  • Santarus Clinical Investigational Site 1014

    Lancaster, Utah

  • Santarus Clinical Investigational Site 1038

    Chesapeake, Virginia

  • Santarus Clinical Investigational Site 1025

    Christiansburg, Virginia

  • Santarus Clinical Investigational Site 4003

    Pleven, Bulgaria

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.